Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 16

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 16
---
 2,022,072 |   |     | $             |   3,380,204 |   |     | $            |   963,855 |   |
| NON-CASH FINANCING ACTIVITIES:                                                                                   |     |               |             |   |     |               |             |   |     |              |           |   |
| Issuance of common shares to Keystone Capital LLC for equity line of credit                                      |     | $             |           - |   |     | $             |     500,000 |   |     | $            |         - |   |
| Issuance of common shares to Arena Investors LP for equity line of credit                                        |     | $             |           - |   |     | $             |     500,000 |   |     | $            |         - |   |
| Conversion of Series A, Series B, Series C and Series D Preferred Stock to common stock                          |     | $             |   2,271,098 |   |     | $             |           - |   |     | $            |         - |   |
| Reclassification of deferred offering costs to additional paid-in capital                                        |     | $             |     112,232 |   |     | $             |           - |   |     | $            |         - |   |
| Reclassification of accrued expenses to accounts payable                                                         |     | $             |   1,143,826 |   |     | $             |           - |   |     | $            |         - |   |
| Issuance of Series D Preferred Stock for investment in equity securities                                         |     | $             |     500,000 |   |     | $             |           - |   |     | $            |         - |   |
| Write off of subscription receivable deemed offering cost                                                        |     | $             |      78,750 |   |     | $             |           - |   |     | $            |         - |   |

<div align='center'>See accompanying notes to the condensed consolidated
financial statements

5

CERO THERAPEUTICS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2025

(Unaudited)</div>

NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Nature of Operations –
CERo Therapeutics Holdings, Inc. (OTC